Peptide library
MID-35
Your guide to this compound.
Evidence in perspective
Cachexia combination experiments and localized iontophoresis in mice address different delivery and outcome questions. Neither establishes human muscle growth or a dose for a purchased MID-35 product.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Mice, including a cancer-cachexia model; the cited papers do not establish human efficacy.
What the sources found
Mouse studies examined muscle preservation with anamorelin and local muscle growth after iontophoresis. Effects varied by muscle and outcome.
What remains unknown
Human benefit, systemic safety, pharmacokinetics and an appropriate human route remain unestablished by these sources.
How it works
Inhibits myostatin signaling in experimental systems.
Inhibits myostatin signaling in experimental systems. Human benefit, systemic safety, pharmacokinetics and an appropriate human route remain unestablished by these sources.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- Safety details remain incomplete in this snapshot; absence of a listed effect does not mean it was excluded.
Contraindications
- This snapshot is not a complete contraindication or interaction review.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
References
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.